

Antwerpen, 12 mei 2016, 18u00 CET

## **Gimv investeert 2.7 miljoen USD in EndoStim in het kader van een totale serie D-financiering van 25 miljoen USD**

EndoStim kondigt vandaag aan dat het in het kader van een serie D-financieringsronde 25 miljoen USD heeft opgehaald bij een investeringssyndicaat bestaande uit Gimv, Wellington Partners, en Edeavour Vision naast de bestaande investeerders in het bedrijf. Deze investering zal worden aangewend om de commercialisering te versnellen en om de klinische proeven van het bedrijf in de Verenigde Staten te financieren.

EndoStim ([www.endostim.com](http://www.endostim.com)) is een medtech bedrijf, gevestigd in St. Louis (Missouri) en Nijmegen (Nederland), dat een neurostimulator heeft ontworpen voor patiënten met Gastro-Oesofageale Reflux-ziekte (GERD). Het bedrijf heeft een stimulator ontwikkeld dat met een minimaal invasieve ingreep kan worden ingebracht. Op lange termijn houdt het reflux onder controle door de normale oesofageale functie te herstellen met behulp van gepersonaliseerde neurostimulatie met minimale energie. De stimulator van EndoStim beschikt reeds over CE-markering voor GERD-patiënten die de symptomen reeds meer dan zes maanden hebben, en is reeds beschikbaar in een aantal Europese landen, Latijns-Amerika en de regio Azië/Stille Oceaan.

De serie D-financiering zal worden aangewend voor verdere commercialisering van de EndoStim-stimulator buiten de Verenigde Staten, voor een gecontroleerde klinische studie in de Verenigde Staten, en de ontwikkeling van volgende generatie stimulators.

Patrick Van Beneden, Partner in Gimv's Health & Care team over deze transactie: *"We zijn erg enthousiast over de technologie van EndoStim en de mogelijke oplossing die het biedt voor patiënten met ernstige reflux. De therapie van EndoStim kan een oplossing bieden voor patiënten bij wie geneesmiddelen een onvoldoende resultaat geven, terwijl de neveneffecten van zwaardere chirurgische ingrepen kunnen worden vermeden."*

Voor meer informatie verwijzen we u graag naar het persbericht van EndoStim in bijlage.

---

## OVER GIMV

Gimv is een Europese investeringsmaatschappij met meer dan drie decennia ervaring in private equity en venture capital. Het bedrijf is genoteerd op Euronext Brussel. Gimv beheert ongeveer 1,8 miljard EUR (inclusief co-investeringspartnerships) aan investeringen in 50 portefeuillebedrijven.

Als erkend marktleider in geselecteerde investeringsplatformen identificeert Gimv ondernemende en innoverende bedrijven met een groot groeipotentieel en begeleidt ze in hun transformatie tot marktleiders. De vier investeringsplatformen zijn: Connected Consumer, Health & Care, Smart Industries en Sustainable Cities. Elk van deze platformen werkt met een bekwaam en toegewijd team in de thuismarkt van Gimv (Benelux, Frankrijk en Duitsland) en kan rekenen op een uitgebreid internationaal netwerk van deskundigen.

Meer informatie over Gimv vindt u op [www.gimv.com](http://www.gimv.com).

---

Voor meer informatie, gelieve contact op te nemen met:

**Patrick Van Beneden**, Partner Health & Care Gimv  
T +32 3 290 21 36 – [patrick.vanbeneden@gimv.com](mailto:patrick.vanbeneden@gimv.com)

**Frank De Leenheer**, Investor Relations & Corporate Communications Manager  
T +32 3 290 22 18 – [frank.deleenheer@gimv.com](mailto:frank.deleenheer@gimv.com)

## **EndoStim Secures \$25 Million in Funding to Expand Commercialization Efforts and Conduct a Pivotal U.S. Clinical Trial**

NIJMEGEN, The Netherlands and ST. LOUIS, MO, May 12, 2016 /PR Newswire/ – EndoStim, Inc., a medical device company that has developed neurostimulation therapy for gastroesophageal reflux disease (GERD), today announced it has completed a Series D financing round of \$25 million. Endeavour Vision, an internationally recognized investor in healthcare and technology companies, led the round, with participation from existing investors, led by Santé Ventures. New investors Wellington Partners and Gimv completed the syndicate.

“Hundreds of millions of patients worldwide suffer from GERD, and many are not optimally treated with long-term proton pump inhibitor medication,” said Doug French, managing director of Santé Ventures and chairman of EndoStim’s Board of Directors. “We believe EndoStim is perfectly positioned to address the therapy gap that exists for patients with severe reflux, which is why we are very excited to welcome such an experienced group of new investors to the EndoStim team.”

EndoStim has developed a unique, minimally-invasive implantable device designed to provide long-term reflux control by restoring normal esophageal function through low-energy personalized neurostimulation. The therapy directly targets the patient's weak or dysfunctional lower esophageal sphincter (LES) muscle between the stomach and the esophagus, often the underlying cause of reflux. Two long-term clinical trials and an ongoing international patient registry continue to demonstrate successful control of abnormal acid in the esophagus and significant improvement in patient quality of life through up to four years of follow-up with an excellent safety profile.

The Series D financing will support expanded commercialization efforts for EndoStim’s minimally-invasive GERD therapy outside the United States; a randomized sham-controlled pivotal trial in the United States; and the development of next generation devices.

“Endeavour Vision is proud to partner with EndoStim, which has created a truly revolutionary, minimally-invasive therapy that provides long-term control of esophageal acid exposure, while avoiding the risk of side effects that is common with traditional anti-reflux surgery,” said Alexander Schmitz, who recently joined the EndoStim board representing Endeavour Vision. “We are confident that EndoStim will ultimately become a standard of care in GERD treatment in the U.S. and worldwide.”

### **About EndoStim**

EndoStim is a medical device company based in St. Louis, Missouri, and Nijmegen, The Netherlands, developing and commercializing a revolutionary treatment for GERD. The EndoStim system is CE Marked for patients with gastro-esophageal reflux disease with symptom duration of six months or longer, and is available in a number of countries throughout Europe, Latin America, and Asia Pacific. The EndoStim system is not approved for sale in the US and is limited by US federal law to investigational use only. For more information, visit [www.endostim.com](http://www.endostim.com).

### **About Endeavour Vision**

Endeavour Vision is an internationally recognized investor in healthcare and technology companies. The team, which partners successful investment professionals with world-class industry veterans, has executed more than 65 investments within its focus verticals. With the recent closing of the Endeavour Medtech Growth Fund, Endeavour Vision is advising one of the largest funds dedicated to helping medical technology companies in Europe and the US to accelerate their global growth and market leadership. For more information, visit [www.endeavourvision.com](http://www.endeavourvision.com).

### **About Santé Ventures**

Santé Ventures is a life sciences venture capital firm that invests exclusively in early-stage companies developing innovative new medical technologies or healthcare delivery models. The firm was founded in 2006 and has \$280 million in capital under management in two funds. For more information, visit [www.santeventures.com](http://www.santeventures.com).

### **About Gimv**

Gimv is a European investment company with over three decades experience in private equity and venture capital. The company is listed on Euronext Brussels. Gimv currently manages around 1.8 billion EUR (including co-investment partnerships) of investments in about 50 portfolio companies.

As a recognized market leader in selected investment platforms, Gimv identifies entrepreneurial and innovative companies with high-growth potential and supports them in their transformation into market leaders. Gimv's four investment platforms are: Connected Consumer, Health & Care, Smart Industries and Sustainable Cities. Each of these platforms works with a skilled and dedicated team across Gimv's home markets of the Benelux, France and Germany and can count on an extended international network of experts. More information on Gimv can be found on [www.gimv.com](http://www.gimv.com).

### **About Wellington Partners**

Wellington Partners is among the most successful pan-European Venture Capital firms. With more than € 800 million under management and offices in Munich, London and Zurich, Wellington Partners invests in start-up companies throughout Europe that have the potential to become global leaders in the areas of digital media, resource efficiency and life sciences. Since 1998, Wellington Partners has invested in more than 100 companies, including publicly listed firms like Actelion, Evolva, Gentical, , Oxford Immunotec, Supersonic Imagine, Wavelight (acquired by Alcon) and Xing as well as privately held companies like AyoxxA, Definiens (acquired by Medimmune), Grandis (acquired by Novartis), G-Therapeutics, ImevaXx, immatics, Immobilienscout24 (acquired by Deutsche Telekom), invendo medical, MPM Medical, MTM Laboratories (acquired by Roche), NEUWAY Pharma, Oxagen/Atopix, Quanta, Rigontec, Sapiens (acquired by Medtronic), Sensimed, Symetis, Spotify and Themis. For further information, please visit [www.wellington-partners.com](http://www.wellington-partners.com).

### **For more information, please contact:**

Eileen Ke

[eke@endostim.com](mailto:eke@endostim.com)